We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amgen (AMGN) Increases Yet Falls Behind Market: What Investors Need to Know
Read MoreHide Full Article
Amgen (AMGN - Free Report) closed at $319.66 in the latest trading session, marking a +0.69% move from the prior day. The stock lagged the S&P 500's daily gain of 0.9%. Elsewhere, the Dow gained 0.81%, while the tech-heavy Nasdaq added 1.22%.
The the stock of world's largest biotech drugmaker has fallen by 2.12% in the past month, leading the Medical sector's loss of 4.05% and undershooting the S&P 500's gain of 3.15%.
The investment community will be paying close attention to the earnings performance of Amgen in its upcoming release. The company is slated to reveal its earnings on October 30, 2024. The company's earnings per share (EPS) are projected to be $5.13, reflecting a 3.43% increase from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $8.51 billion, reflecting a 23.24% rise from the equivalent quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $19.49 per share and a revenue of $33.21 billion, signifying shifts of +4.5% and +17.82%, respectively, from the last year.
Investors should also take note of any recent adjustments to analyst estimates for Amgen. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.01% decrease. Amgen is currently a Zacks Rank #3 (Hold).
From a valuation perspective, Amgen is currently exchanging hands at a Forward P/E ratio of 16.29. This signifies a discount in comparison to the average Forward P/E of 22.61 for its industry.
We can additionally observe that AMGN currently boasts a PEG ratio of 2.82. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical - Biomedical and Genetics was holding an average PEG ratio of 2.31 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 73, which puts it in the top 29% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Amgen (AMGN) Increases Yet Falls Behind Market: What Investors Need to Know
Amgen (AMGN - Free Report) closed at $319.66 in the latest trading session, marking a +0.69% move from the prior day. The stock lagged the S&P 500's daily gain of 0.9%. Elsewhere, the Dow gained 0.81%, while the tech-heavy Nasdaq added 1.22%.
The the stock of world's largest biotech drugmaker has fallen by 2.12% in the past month, leading the Medical sector's loss of 4.05% and undershooting the S&P 500's gain of 3.15%.
The investment community will be paying close attention to the earnings performance of Amgen in its upcoming release. The company is slated to reveal its earnings on October 30, 2024. The company's earnings per share (EPS) are projected to be $5.13, reflecting a 3.43% increase from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $8.51 billion, reflecting a 23.24% rise from the equivalent quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $19.49 per share and a revenue of $33.21 billion, signifying shifts of +4.5% and +17.82%, respectively, from the last year.
Investors should also take note of any recent adjustments to analyst estimates for Amgen. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.01% decrease. Amgen is currently a Zacks Rank #3 (Hold).
From a valuation perspective, Amgen is currently exchanging hands at a Forward P/E ratio of 16.29. This signifies a discount in comparison to the average Forward P/E of 22.61 for its industry.
We can additionally observe that AMGN currently boasts a PEG ratio of 2.82. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical - Biomedical and Genetics was holding an average PEG ratio of 2.31 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 73, which puts it in the top 29% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.